VantAI

VantAI is an AI application focused on generative AI-enabled drug discovery. Their mission is to unlock a new chapter in medicine by making protein interactions programmable. They have an integrated discovery platform with phase-shifting technologies designed to unlock the full potential of the proximity modulator modality. VantAI collaborates with industry leaders to build the future of therapeutic design. The company has launched Neo-1, the first AI model to rewire molecular interactions by unifying structure prediction and generation.

Exscientia is a technology-driven drug design and development company that combines precision design with integrated experimentation to create more effective medicines for patients faster. They operate at the interfaces of human ingenuity, artificial intelligence (AI), automation, and physical engineering, pioneering the use of AI in drug discovery. Exscientia aims to change the underlying economics of drug discovery by rapidly advancing the best scientific ideas into medicines for patients.

The Institute for Protein Design is a research institute at the University of Washington that uses computational design to create new proteins that solve modern challenges in medicine, technology, and sustainability. The institute's research focuses on developing new protein therapeutics, vaccines, drug delivery systems, biological devices, self-assembling nanomaterials, and bioactive peptides. The institute also has a strong commitment to responsible AI development and has developed a set of principles to guide its use of AI in research.

The website features Grok-1.5, an AI application that bridges the gap between the digital and physical worlds through its multimodal model. Grok-1.5 boasts enhanced reasoning capabilities and a context length of 128,000 tokens. Additionally, the platform offers PromptIDE, an IDE for prompt engineering and interpretability research, allowing users to create and share complex prompts in Python. Grok, an AI modeled after the Hitchhiker’s Guide to the Galaxy, is also available on the site, providing answers to a wide range of questions and even suggesting relevant queries. The platform aims to facilitate knowledge sharing and exploration through advanced AI technologies.

Tempus is an AI-enabled precision medicine company that brings the power of data and artificial intelligence to healthcare. With the power of AI, Tempus accelerates the discovery of novel targets, predicts the effectiveness of treatments, identifies potentially life-saving clinical trials, and diagnoses multiple diseases earlier. Tempus' innovative technology includes ONE, an AI-enabled clinical assistant; NEXT, which identifies and closes gaps in care; LENS, which finds, accesses, and analyzes multimodal real-world data; and ALGOS, algorithmic models connected to Tempus' assays to provide additional insight.

Tempus is an AI-enabled precision medicine company that brings the power of data and artificial intelligence to healthcare. With the power of AI, Tempus accelerates the discovery of novel targets, predicts the effectiveness of treatments, identifies potentially life-saving clinical trials, and diagnoses multiple diseases earlier. Tempus's innovative technology includes ONE, an AI-enabled clinical assistant; NEXT, a tool to identify and close gaps in care; LENS, a platform to find, access, and analyze multimodal real-world data; and ALGOS, algorithmic models connected to Tempus's assays to provide additional insight.

Atomwise is an artificial intelligence (AI)-driven drug discovery company that uses machine learning to discover and develop new small molecule medicines. The company's AI engine combines the power of convolutional neural networks with massive chemical libraries to identify new drug candidates. Atomwise has a wholly owned pipeline of drug discovery programs and also partners with other pharmaceutical companies to co-develop drugs. The company's investors include prominent venture capital firms and pharmaceutical companies.

Atomwise is an AI-powered drug discovery company that uses machine learning to identify new small molecule medicines. The company's platform combines the power of convolutional neural networks with massive chemical libraries to discover new drug candidates. Atomwise has a portfolio of wholly owned and co-developed pipeline assets, and is backed by prominent investors.

Structurepedia is an AI-powered platform that maps the structure of knowledge by providing structured and interactive information on various topics, including neural network architecture variants and other important concepts in machine learning and artificial intelligence. It offers a new way to learn by allowing users to explore topics through visual diagrams and detailed resources, making it easier to understand complex information. Structurepedia aims to revolutionize the way people access and comprehend knowledge in the age of AI, acting as a modern encyclopedia and search engine tailored for the AI era.

TextLayer is an AI-powered research companion that simplifies access to the latest research in machine learning. It empowers users to turn new discoveries into powerful solutions by providing personalized recommendations, AI-generated insights, and implementation support. The platform offers curated AI-generated summaries of research papers, tailored recommendations, and a chat integration for interacting with AI. TextLayer aims to bridge the gap between complex ML research papers and understanding, fostering curiosity, innovation, and shaping the future of Artificial Intelligence.

The Deepfake Detection Challenge Dataset is a project initiated by Facebook AI to accelerate the development of new ways to detect deepfake videos. The dataset consists of over 100,000 videos and was created in collaboration with industry leaders and academic experts. It includes two versions: a preview dataset with 5k videos and a full dataset with 124k videos, each featuring facial modification algorithms. The dataset was used in a Kaggle competition to create better models for detecting manipulated media. The top-performing models achieved high accuracy on the public dataset but faced challenges when tested against the black box dataset, highlighting the importance of generalization in deepfake detection. The project aims to encourage the research community to continue advancing in detecting harmful manipulated media.

Genesis Therapeutics is a cutting-edge platform that leverages molecular AI technology to discover and develop highly potent and selective medicines. Their proprietary AI platform, GEMS, combines AI and physics research to target challenging protein structures and create innovative drug candidates with exceptional efficacy. The company's success is driven by a collaborative approach, bringing together experts in AI and biotech to tackle complex drug discovery challenges.

Aquarium is an AI tool that accelerates the process of building and deploying production AI systems. The platform has been instrumental in enhancing the capabilities of AI models, particularly in computer vision and natural language processing domains. By leveraging generative AI technology, Aquarium aims to bring value to a vast user base, spanning from college students to enterprises. The recent integration with Notion signifies a strategic move towards making AI more accessible and impactful in everyday life.

OpenAI Strawberry Model is a cutting-edge AI initiative that represents a significant leap in AI capabilities, focusing on enhancing reasoning, problem-solving, and complex task execution. It aims to improve AI's ability to handle mathematical problems, programming tasks, and deep research, including long-term planning and action. The project showcases advancements in AI safety and aims to reduce errors in AI responses by generating high-quality synthetic data for training future models. Strawberry is designed to achieve human-like reasoning and is expected to play a crucial role in the development of OpenAI's next major model, codenamed 'Orion.'

FlyPix is an AI-enabled geospatial solutions platform that leverages advanced AI technology to transform object detection, localization, tracking, and monitoring in the field of geospatial technology. The platform offers a wide range of capabilities, including AI-driven object analysis, change and anomaly detection, dynamic tracking, and custom use cases tailored to meet unique industry needs. FlyPix aims to provide unparalleled precision and efficiency in operations by converting complex imagery into actionable, geo-referenced insights.

Iambic Therapeutics is a cutting-edge AI-driven drug discovery platform that tackles the most challenging design problems in drug discovery, addressing unmet patient need. Its physics-based AI algorithms drive a high-throughput experimental platform, converting new molecular designs to new biological insights each week. Iambic's platform optimizes target product profiles, exploring multiple profiles in parallel to ensure that molecules are designed to solve the right problems in disease biology. It also optimizes drug candidates, deeply exploring chemical space to reveal novel mechanisms of action and deliver diverse high-quality leads.

Moonvalley is a research company focused on developing generative media using deep learning technology. The team consists of experienced researchers, engineers, and artists from renowned companies such as Deepmind, IBM, and Microsoft. Moonvalley aims to revolutionize the field of generative video production through cutting-edge AI techniques.

Moonvalley is a research company focused on developing cutting-edge generative media technologies. The team consists of top researchers, engineers, and artists with backgrounds in leading tech companies. Moonvalley specializes in advanced video and image machine learning models, aiming to shape the future of media creation.

The DARPA's Artificial Intelligence Cyber Challenge (AIxCC) is an AI-driven cybersecurity tool developed in collaboration with ARPA-H and various industry experts like Anthropic, Google, Microsoft, OpenAI, and others. It aims to safeguard critical software infrastructure by utilizing AI technology to enhance cybersecurity measures. The tool provides a platform for experts in AI and cybersecurity to come together and address the evolving threats in the digital landscape.

VantAI is an AI application focused on generative AI-enabled drug discovery. Their mission is to unlock a new chapter in medicine by making protein interactions programmable. They have an integrated discovery platform with phase-shifting technologies designed to unlock the full potential of the proximity modulator modality. VantAI collaborates with industry leaders to build the future of therapeutic design. The company has launched Neo-1, the first AI model to rewire molecular interactions by unifying structure prediction and generation.

Synthace is a software and expertise platform designed for Discovery Biology Teams to streamline and optimize their experiments in assay development, media optimization, and purification process development. The platform offers software solutions, training, and on-site support from specialists to help scientists conduct experiments more efficiently and effectively. By leveraging multifactorial methods and automation, Synthace aims to accelerate drug discovery processes and deliver faster, definitive results.

HUAWEI Cloud Pangu is an AI tool designed for accelerating drug discovery by optimizing drug molecules. It offers features such as Molecule Search, Molecule Optimizer, and Pocket Molecule Design. Users can submit molecules for optimization and view historical optimization results. The tool is based on the MindSpore framework and has been visited over 300,000 times since August 23, 2021.

VantAI is an AI application focused on generative AI-enabled drug discovery. Their mission is to unlock a new chapter in medicine by making protein interactions programmable. They have an integrated discovery platform with phase-shifting technologies designed to unlock the full potential of the proximity modulator modality. VantAI collaborates with industry leaders to build the future of therapeutic design. The company has launched Neo-1, the first AI model to rewire molecular interactions by unifying structure prediction and generation.

CEBRA is a machine-learning method that compresses time series data to reveal hidden structures in the variability of the data. It excels in analyzing behavioral and neural data simultaneously, allowing for the decoding of activity from the visual cortex of the mouse brain to reconstruct viewed videos. CEBRA is a novel encoding method that leverages both behavioral and neural data to produce consistent and high-performance latent spaces, enabling the mapping of space, uncovering complex kinematic features, and providing rapid, high-accuracy decoding of natural movies from the visual cortex.

Mind-Video is an AI tool that focuses on high-quality video reconstruction from brain activity data. It bridges the gap between image and video brain decoding by utilizing masked brain modeling, multimodal contrastive learning, spatiotemporal attention, and co-training with an augmented Stable Diffusion model. The tool aims to recover accurate semantic information from fMRI signals, enabling the generation of realistic videos based on brain activities.

Boff.ai is an AI tool that connects professionals with academia to unlock opportunities and funding for research and development teams. It helps users ask specific questions across various topics and sources replies from experts in the field. The platform ensures privacy and focuses on solutions required, making it a trusted resource for 30,000 academics and R&D professionals.

Modality.AI is an AI application that has developed an automated, clinically validated system to assess neurological and psychiatric states both in clinic and remotely. The platform utilizes conversational AI to monitor conditions accurately and consistently, allowing researchers and clinicians to review data in near real-time and monitor treatment response over time. Modality.AI collaborates with world-class AI/Machine Learning experts and leading institutions to provide a HIPAA-compliant system for assessing various indications such as ALS, Parkinson's, depression, autism, Huntington's Disease, schizophrenia, and mild cognitive impairment. The platform enables convenient monitoring at home through streaming and analysis of speech and facial responses, without the need for special software or apps. Modality.AI is accessible on various devices with a browser, webcam, and microphone, offering a new approach to efficient and cost-effective clinical trials.

Neuralink is a pioneering brain-computer interface (BCI) application that aims to redefine human capabilities by creating a generalized brain interface to restore autonomy to individuals with unmet medical needs. The application focuses on developing fully implantable BCIs that allow users, particularly those with quadriplegia, to control computers and mobile devices using their thoughts. Neuralink's innovative technology includes advanced chips, biocompatible enclosures, and surgical robots for precise implantation. The application prioritizes safety, accessibility, and reliability in its engineering process, with future goals of restoring vision, motor function, and speech capabilities.

Ascenscia is a specialized AI voice assistant designed to streamline lab digitization processes. It integrates with laboratory software and machines to enable hands-free interactions, automating data collection, optimizing workflows, and accelerating R&D cycles. Ascenscia offers features such as data accessibility, data capturing, inventory access, and additional task management. The application is designed for scientific labs, addressing concerns with precision, safety, and adaptability. It boasts high accuracy in understanding scientific terminologies, end-to-end data encryption, multi-lingual support, and customization options for different lab workflows.

Nucleai is an AI-driven spatial biomarker analysis tool that leverages military intelligence-grade geospatial AI methods to analyze complex cellular interactions in a patient's biopsy. The platform offers a first-of-its-kind multimodal solution by ingesting images from various modalities and delivering actionable insights to optimize biomarker scoring, predict response to therapy, and revolutionize disease diagnosis and treatment.

Exscientia is a technology-driven drug design and development company that combines precision design with integrated experimentation to create more effective medicines for patients faster. They operate at the interfaces of human ingenuity, artificial intelligence (AI), automation, and physical engineering, pioneering the use of AI in drug discovery. Exscientia aims to change the underlying economics of drug discovery by rapidly advancing the best scientific ideas into medicines for patients.

Paige is a leading AI company revolutionizing pathology with next-generation technology. They provide diagnostic and biomarker AI, predictive analytics technology, and AI-assisted applications to support cancer detection, subtyping, and molecular biomarker discovery from tissue samples. Paige offers a range of AI suites for prostate, breast, colon, and PanCancer, as well as the innovative Paige Alba™ multi-modal co-pilot. Their advanced AI technology and services help streamline AI development, optimize existing applications, and drive groundbreaking advancements in cancer care.

Undermind is an AI-powered scientific research assistant that revolutionizes the way researchers access and analyze academic papers. By utilizing intelligent language models, Undermind reads and synthesizes information from hundreds of papers to provide accurate and comprehensive results. Researchers can describe their queries in natural language, and Undermind assists in finding relevant papers, brainstorming questions, and discovering crucial insights. Trusted by researchers across various fields, Undermind offers a unique approach to literature search, surpassing traditional search engines in accuracy and efficiency.

Salt AI is a development engine tailored for life sciences organizations, aiming to accelerate advancements in the field by enabling faster adoption and utilization of AI technologies. The platform offers reliable and reproducible AI processes, optimized for speed and efficiency, and promotes transparency and collaboration within workflows. With a focus on supporting best-in-class life sciences research models, Salt AI empowers users to enhance their understanding of biological processes through flexible and performant AI solutions.

Cradle is a protein engineering platform that uses machine learning to design improved protein sequences. It allows users to import assay data, generate new sequences, test them in the lab, and import the results to improve the model. Cradle can be used to optimize multiple properties of a protein simultaneously, and it has been used by leading biotech teams to accelerate new and ongoing projects.

Owkin is a full-stack AI biotech company that integrates the best of human and artificial intelligence to deliver better drugs and diagnostics at scale. By understanding complex biology through AI, Owkin identifies new treatments, de-risks and accelerates clinical trials, and builds diagnostic tools to reduce time to impact for patients.

Cerebras is an AI tool that offers products and services related to AI supercomputers, cloud system processors, and applications for various industries. It provides high-performance computing solutions, including large language models, and caters to sectors such as health, energy, government, scientific computing, and financial services. Cerebras specializes in AI model services, offering state-of-the-art models and training services for tasks like multi-lingual chatbots and DNA sequence prediction. The platform also features the Cerebras Model Zoo, an open-source repository of AI models for developers and researchers.

CCDS (Center for Computational & Data Sciences) is a research center at Independent University Bangladesh dedicated to artificial intelligence, data sciences, and computational science. The center has various wings focusing on AI, computational biology, physics, data science, human-computer interaction, and industry partnerships. CCDS explores the use of computation to understand nature and society, uncover hidden stories in data, and tackle complex challenges. The center collaborates with institutions like CERN and the Dunlap Institute for Astronomy and Astrophysics.

Variational AI is a company that uses generative AI to discover novel drug-like small molecules with optimized properties for defined targets. Their platform, Enki™, is the first commercially accessible foundation model for small molecules. It is designed to make generating novel molecule structures easy, with no data required. Users simply define their target product profile (TPP) and Enki does the rest. Enki is an ensemble of generative algorithms trained on decades worth of experimental data with proven results. The company was founded in September 2019 and is based in Vancouver, BC, Canada.

Insitro is a drug discovery and development company that uses machine learning and data to identify and develop new medicines. The company's platform integrates in vitro cellular data produced in its labs with human clinical data to help redefine disease. Insitro's pipeline includes wholly-owned and partnered therapeutic programs in metabolism, oncology, and neuroscience.

Atomwise is an artificial intelligence (AI)-driven drug discovery company that uses machine learning to discover and develop new small molecule medicines. The company's AI engine combines the power of convolutional neural networks with massive chemical libraries to identify new drug candidates. Atomwise has a wholly owned pipeline of drug discovery programs and also partners with other pharmaceutical companies to co-develop drugs. The company's investors include prominent venture capital firms and pharmaceutical companies.

XtalPi is a world-leading technology company driven by artificial intelligence (AI) and robotics to innovate in the fields of life sciences and new materials. Founded in 2015 at the Massachusetts Institute of Technology (MIT), the company is committed to realizing digital and intelligent innovation in the fields of life sciences and new materials. Based on cutting-edge technologies and capabilities such as quantum physics, artificial intelligence, cloud computing, and large-scale experimental robot clusters, the company provides innovative technologies, services, and products for global industries such as biomedicine, chemicals, new energy, and new materials.

Allchemy is a resource-aware AI platform for drug discovery. It combines state-of-the-art computational synthesis with AI algorithms to predict molecular properties. Within minutes, Allchemy creates thousands of synthesizable lead candidates meeting user-defined profiles of drug-likeness, affinity towards specific proteins, toxicity, and a range of other physical-chemical measures. Allchemy encompasses the entire resource-to-drug design process and has been used in academic, corporate and classified environments worldwide to: Design synthesizable leads targeting specific proteins Evolve scaffolds similar to desired drugs Design “circular” drug syntheses from renewable materials Interface with and instruct automated synthesis platforms and optimize pilot-scale processes Operate “iterative synthesis” schemes Predict side reactions and create forensic “synthetic signatures” of hazardous/toxic molecules Design synthetic degradation and recovery cycles for various types of feedstocks and functional target molecules

Iambic Therapeutics is a cutting-edge AI-driven drug discovery platform that tackles the most challenging design problems in drug discovery, addressing unmet patient need. Its physics-based AI algorithms drive a high-throughput experimental platform, converting new molecular designs to new biological insights each week. Iambic's platform optimizes target product profiles, exploring multiple profiles in parallel to ensure that molecules are designed to solve the right problems in disease biology. It also optimizes drug candidates, deeply exploring chemical space to reveal novel mechanisms of action and deliver diverse high-quality leads.